Alachua, Florida – Officials at RTI Surgical Inc. (RTI), a leading global surgical implant company, announce the full market launch of the Streamline OCT System. The system is designed to promote fusion of the occipto-cervico-thoracic spine (or occiput-T3). RTI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the system in March 2014.
The Streamline OCT System is intended for use in the treatment of spinal stenosis, tumors, degenerative disc disease, and spondylolisthesis, among others. It allows a rigid construct to be created from occiput to T3 by offering a broad range of implants.
“The Streamline OCT System is another exciting addition to our spine portfolio,” said Brian K. Hutchison, RTI Surgical president and CEO. “We are proud to have a system that offers a range of implants where surgeons can tailor treatment for their patients and provide a more streamlined surgical experience.”
The system is the first to offer a high-angle pedicle screw capable of achieving 60 degrees of angulation in any direction, providing greater intraoperative flexibility and options for screw placement. Streamline OCT also offers a unique occipital plate design that reduces the need for extreme rod bends.
Dr. Anthony Lapinsky, board-certified orthopedic surgeon at Premier Orthopaedics and Sports Medicine, Bloomingfield, NJ and a Fellow with the American Academy of Orthopaedic Surgeons, is one of the design surgeons for this system.
“The Streamline OCT System, with its unsurpassed modularity, ensures I can manage the variety of clinical challenges I come across in my practice,” Lapinsky said. “This is due, in large part, to a number of unique implant options, including the highest angle screw on the market.”
Source: RTI Surgical Inc.